|
1 Indications And Usage Sandostatin Lar Depot 10 Mg, 20 Mg, And 30 Mg Is Indicated In Patients In Whom Initial Treatment With Sandostatin Injection Has Been Shown To Be Effective And Tolerated. Sandostatin Lar Depot Is A Somatostatin Analogue Indicated For: Treatment In Patients Who Have Responded To And Tolerated Sandostatin Injection Subcutaneous Injection For: Acromegaly ( 1.1 ) Severe Diarrhea/flushing Episodes Associated With Metastatic Carcinoid Tumors ( 1.2 ) Profuse Watery Diarrhea Associated With Vasoactive Intestinal Peptide (Vip) Secreting Tumors ( 1.3 ) 1.1 Acromegaly Long-Term Maintenance Therapy In Acromegalic Patients Who Have Had An Inadequate Response To Surgery And/or Radiotherapy, Or For Whom Surgery And/or Radiotherapy, Is Not An Option. The Goal Of Treatment In Acromegaly Is To Reduce Gh And Igf-1 Levels To Normal [See Clinical Studies (14), Dosage And Administration (2)] . 1.2 Carcinoid Tumors Long-Term Treatment Of The Severe Diarrhea And Flushing Episodes Associated With Metastatic Carcinoid Tumors. 1.3 Vasoactive Intestinal Peptide Tumors (Vipomas) Long-Term Treatment Of The Profuse Watery Diarrhea Associated With Vip-Secreting Tumors. 1.4 Important Limitations Of Use In Patients With Carcinoid Syndrome And Vipomas, The Effect Of Sandostatin Injection And Sandostatin Lar Depot On Tumor Size, Rate Of Growth And Development Of Metastases, Has Not Been Determined.
|